Sangamo Therapeutics

SGMO · NASDAQ

$0.11+$0.0088 (+8.70%)TodayMarket closed · Oct 20, 3:59 PM ET

Prev close $0.1012

SGMO analyst rating

BuyConsensus of 2 analysts over the last 12 months. 50% rate it a buy.

Strong buy0
Buy1
Hold1
Underperform0
Sell0

12-month price target · 6 analysts

Average $2.61 (+2276.1% upside)

Low: $1.26
Now: $0.11
High: $5.25

Upgrades and downgrades

The latest rating actions, newest first

SGMO analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
HC Wainwright & Co.	Feb 10, 2026	Maintains	Buy	$10.00	33%
Barclays	Nov 7, 2025	Downgrade	Overweight → Equal-Weight	$5.00 → $1.00	42%

The case for and against

Updated Feb 9, 2026

Bull case

Sangamo Therapeutics has received FDA agreement that data from their Phase 1/2 STAAR trial can support an Accelerated Approval BLA filing for their gene therapy isa-vec targeting symptomatic Fabry disease, which highlights the potential for regulatory approval and market entry. The therapy demonstrated a positive mean annualized estimated glomerular filtration rate (eGFR) slope, reflecting significant renal function improvement, and maintained elevated α-Gal A enzyme levels alongside stability in cardiac structure and function for up to 4.5 years in treated patients. The promising safety profile and demonstrated long-term efficacy of isa-vec further positions Sangamo's pipeline favorably in the genomic medicine landscape, reinforcing a positive outlook for the company's stock.

Bear case

Sangamo Therapeutics's financial performance has been hindered by significant operating losses and high research and development expenditures, raising concerns about its ability to achieve profitability in the near future. Additionally, the company's pipeline, while varied, has faced delays and challenges in clinical development, leading to uncertainty regarding the successful commercialization of its products. Lastly, the reliance on partnerships for key programs introduces further risks, as potential collaborators may alter their commitments or funding based on their own strategic priorities.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.